###### Strengths and limitations of this study

-   Large sample size and long follow-up time were employed to evaluate the impacts of epidural analgesia on long-term outcomes after lung cancer surgery.

-   Propensity score matching was used to deal with possible imbalances in collected variables.

-   Epidural assignment was not randomised, clinical care was not standardised and potential selection bias cannot be ruled out.

-   Effects of unmeasured confounders on outcomes after lung cancer surgery cannot be further evaluated.

Introduction {#s1}
============

Lung cancer is the most commonly diagnosed malignancy worldwide, and its incidence continues to grow.[@R1] An estimated 2.1 million new cases of lung cancer were diagnosed and 1.76 million lung cancer deaths occurred globally in 2018.[@R1] Surgical removal of the primary tumour is the mainstay of treatment for patients with non-small-cell lung cancer staged I through IIIA.[@R2] However, surgical dissection and manipulation are associated with unintentional dispersal of cancer cells into the blood and lymphatic systems.[@R3] Whether the residual neoplastic cell would develop into a metastasis depends on the perioperative immune competence of the patient. Surgically induced stress hormone, as well as inhaled volatile anaesthetics and systemic opioids, can diminish natural killer cell function, the primary defense against cancer cells.[@R4]

Opioids inhibit components of both cell-mediated and humoral immunity.[@R5] Morphine also has proangiogenic properties that may promote dissemination of angiogenesis-dependent tumours.[@R6] Inflammatory cytokines have been shown to regulate the expression of the mu-opioid receptor (MOR) gene, highlighting an interaction between the opioid and immune systems.[@R7] It is noted that the MOR is over-expressed in several types of lung cancer and it promotes opioid- and growth factor-induced proliferation and migration in human lung cancer cells.[@R8] Furthermore, silencing the MOR greatly reduced opioid-induced tumour growth and metastasis in vitro.[@R9]

Anaesthetic management in primary cancer surgery has been proposed to impact recurrence or metastases, including blood transfusion,[@R10] narcotics consumption[@R11] and analgesic techniques.[@R14] Thoracic epidural analgesia, commonly used for the management of postoperative pain, has been shown to reduce mortality, respiratory complications and opioid consumption and improved time to ambulation in thoracic surgeries.[@R15] However, the effect of epidural analgesia on oncological outcomes after lung cancer resection remains unclear. It is hypothesised that epidural analgesia may reduce tumour growth and spread through its opioid and general anaesthetic sparing and surgical stress alleviating properties, but only one retrospective study with limited sample size is available for this issue.[@R16] Therefore, we conducted this retrospective cohort study to investigate the relationship between perioperative thoracic epidural analgesia and cancer recurrence or overall survival in patients following surgical resection for non-small-cell lung cancer. The effects of other major prognostic factors were assessed as well to determine the significant predictors of oncological outcomes after lung cancer resection.

Methods {#s2}
=======

Setting and patient selection {#s2a}
-----------------------------

Patients undergoing surgical resection of pulmonary neoplasms between January 2005 and December 2015 at our hospital were retrospectively identified from the institutional electronic medical database. Patients with secondary lung cancer, small cell lung cancer, stage IV disease determined at the time of surgery or missing data about demographics, pathological details or postoperative analgesic were excluded from the study ([figure 1](#F1){ref-type="fig"}). Patients were analysed in two groups: those receiving general anaesthesia with perioperative epidural analgesia and their counterparts receiving general anaesthesia without epidural analgesia.

![Flow diagram for patient inclusion.](bmjopen-2018-027618f01){#F1}

Analgesia management {#s2b}
--------------------

All patients undergoing open thoracotomy or video-assisted thoracoscopic surgery at our hospital were offered the choice of epidurals with preoperative catheter placement or intravenous analgesia with a demand pump. If epidural analgesia was selected, an epidural catheter was typically placed at a middle thoracic region (eg, T6--T8) and assessed its function with a test dose of local anaesthetic preoperatively. Epidural analgesia was started intraoperatively with local anaesthetic (bupivacaine 0.25% or 0.5%) with or without fentanyl 1--2 µg/mL at an infusion rate of 5--10 mL/hour, continued postoperatively for 48--72 hours, and switched to oral acetaminophen or non-steroidal anti-inflammatory drugs thereafter. Typically, patients undergoing lung cancer surgery received intravenous fentanyl 50--150 µg for anaesthetic induction. Patients with effective epidurals were rarely given additional opioids perioperatively. If patients refused epidurals or it was contraindicated, an intravenous patient-controlled analgesia was administered via an ambulatory infusion pump (Gemstar Yellow, Hospira, Illinois, USA) programmed to deliver morphine sulfate 1 mg/mL in normal saline, at a demand dose of 1 mg with a lockout time of 6 min.

Data retrieval {#s2c}
--------------

An electronic medical database was used to determine the baseline clinicopathological risk factors for cancer recurrence and mortality. The following data were obtained from medical records: demographic characteristics; the Eastern Cooperative Oncology Group (ECOG) performance score[@R17]; coexisting diseases (chronic obstructive pulmonary disease, diabetes, chronic kidney disease and so on); preoperative pulmonary function tests (forced vital capacity, forced expiratory volume in one second and their predicted percentages); pretreatment carcinoembryonic antigen (CEA) level[@R18]; anaesthesia time, perioperative packed red blood cell (pRBC) transfusion[@R19]; pathologic features (tumour differentiation, microscopic necrosis,[@R20] lymphovascular invasion[@R21] and perineural invasion)[@R22]; whether preoperative or postoperative adjuvant chemotherapy or radiotherapy was used and each patient's current status as determined by documentation of follow-up visits to the hospital's outpatient clinic or subsequent admissions. Tumour nodes metastasis (TNM) staging was also obtained from the record and translated into stages I--III according to the American Joint Committee on Cancer criteria (AJCC-7 staging system).[@R23] Adjuvant therapies given in the form of chemotherapy (cisplatin-gemcitabine, cisplatin-paclitaxel, cisplatin-docetaxel or carboplatin-paclitaxel) or radiotherapy were at the discretion of surgeons and patients, and was defined as any therapy given within 90 days of surgery. The radiologists and thoracic surgeons of our hospital determined whether cancer recurred or not, which was mainly based on imaging studies (CT, MRI, bone scan and so on) and defined by response evaluation criteria in solid tumours guidelines.[@R24] Pathology-proven second primary lung cancer was not considered as a recurrent disease. At our hospital, close surveillance was performed for survivors of lung cancer following definitive surgical therapy, including chest CT every 6 months for at least the first 2 years, and annually thereafter. The follow-up rates of this cohort were 95.3%, 88.7% and 78.8% in the end of the postoperative first, third and fifth year, respectively (online [supplementary table 1](#SP1){ref-type="supplementary-material"}). The date of death was determined based on medical record or death certificate.
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Medical records of all the patients included were extracted by specialist anaesthesiologists who were not involved in data analysis. The quality of the extracted data was verified through random sampling by the authors. Data were collected up to the end of May 2017.

The primary endpoint was recurrence-free survival, which was defined as time from the date of surgery to the date of cancer recurrence. The secondary endpoint was overall survival, defined as time from the date of surgery to the date of death. For those without the event of cancer recurrence or death, their survival times were regarded as the corresponding censored observations with the last visit date used as the censored date.

Statistical analysis {#s2d}
--------------------

The comparisons of patient characteristics between the epidural and non-epidural groups were performed using Χ^2^ tests for categorical variables and either t tests or Wilcoxon rank sum tests for continuous variables, as appropriate. The Kaplan-Meier method and log rank test were used to compare recurrence-free and overall survival distributions between the two groups. Univariate Cox regression analysis was used to evaluate the effects of epidural analgesia and other variables collected in the study on recurrence-free or overall survival. Significant predictors of recurrence-free or overall survival in the univariate analysis were used as candidates for stepwise model selection processes in the following multivariable analysis. The entry and exit criteria of significance level were set at 0.05 and 0.1, respectively, to select factors associated with recurrence-free and overall survival in the multivariable analysis. Afterward the effects of epidural analgesia adjusted for the selected predictors in the multivariable analysis on recurrence-free and overall survival were further evaluated.

To account for the potential imbalance in measured confounders related to cancer recurrence or survival of lung cancer between epidural and non-epidural groups, propensity scores based on a collection of patient characteristics was developed to estimate the probability of receiving epidurals (online [supplementary table 2](#SP1){ref-type="supplementary-material"}). Propensity score matching was performed as the primary analysis using a calliper with width equal to 0.2 of the SD of the logit of the propensity score to ensure sufficient balance in collected variables between matching pairs.[@R25] Imbalance of the distribution of baseline attributes between groups was measured by standardised difference, the difference in mean, proportion or rank divided by the pooled SE, expressed as percentage and was defined as absolute value greater than 20.[@R26] For sensitivity analysis, all subjects were divided into five equal-size groups using the quintiles of the estimated propensity score and stratified Cox regression analysis was conducted to obtain a pooled HR across the five strata to ensure the consistency among different estimates of the effects of epidurals on cancer recurrence or overall survival. The significance level of all hypotheses was 0.05 for a two-sided test. IBM SPSS Statistics for Windows V.22.0 (IBM Corp.) was used for all analyses.

Patient and public involvement {#s2e}
------------------------------

This study is a retrospective analysis using the institutional medical database. There was no patient involved in the recruitment to and conduct of the study.

Results {#s3}
=======

Total of 2191 patients were included in this study and 1799 (82.1%) of them received epidural analgesia. There were some differences in the distributions of baseline characteristics between groups, including less thoracoscopic surgery (standardised difference=36.1) and longer follow-up time (standardised difference=20.4) in epidural group ([table 1](#T1){ref-type="table"}). The rate of epidural placement declined because more resections of lung cancer were done with thoracoscopic technique at our hospital in recent years (online [supplementary table 3](#SP1){ref-type="supplementary-material"}). Those not receiving epidurals, as mentioned above, had intravenous patient-controlled opioid analgesia. [Table 2](#T2){ref-type="table"} shows the details of cancer stages and pathological features of the two groups. The epidural group had higher rate of lymphocytic infiltration. After propensity score matching, the final sample of 372 matched pairs of patients was analysed and no significant difference was found in demographical or pathological characteristics between groups ([table 1](#T1){ref-type="table"}).

###### 

Patient demographics

                                 Before matching     After matching                                                     
  ------------------------------ ------------------- ------------------- ------ ------------------- ------------------- ------
  Age, year                      64±11               64±11               0.1    64±12               64±11               5.8
  Sex, male                      918 (51.0%)         194 (49.5%)         3.1    192 (51.6%)         183 (49.2%)         4.8
  ASA physical status≥3          424 (23.6%)         109 (27.8%)         9.7    104 (28.0%)         100 (26.9%)         2.4
  ECOG PS≥1                      549 (30.5%)         130 (33.2%)         5.7    132 (35.5%)         117 (31.5%)         8.6
  Comorbidities                                                                                                         
   COPD                          474 (26.3%)         107 (27.3%)         2.1    102 (27.4%)         100 (26.9%)         1.2
   Diabetes                      297 (16.5%)         56 (14.3%)          6.2    56 (15.1%)          52 (14.0%)          3.1
   Coronary artery disease       171 (9.5%)          41 (10.5%)          3.2    41 (11.0%)          39 (10.5%)          1.7
   Heart failure                 74 (4.1%)           21 (5.4%)           5.9    15 (4.0%)           19 (5.1%)           5.2
   Stroke                        60 (3.3%)           18 (4.6%)           6.4    25 (6.7%)           17 (4.6%)           9.3
   Chronic kidney disease        141 (7.8%)          35 (8.9%)           3.9    25 (6.7%)           31 (8.3%)           6.1
  Pulmonary function test                                                                                               
   FVC (L)                       2.88±0.76           2.81±0.73           9.5    2.83±0.76           2.82±0.73           1.9
   % Predicted                   87.6±15.7           85.9±15.6           10.8   87.1±16.3           86.1±15.6           6.4
   FEV~1~ (L)                    2.22±0.62           2.15±0.60           12.3   2.17±0.62           2.16±0.59           2.8
   % Predicted                   86.3±16.4           83.8±16.6           15.5   85.4±16.3           84.1±16.4           7.8
  Pretreatment CEA (μg/L)        2.4 (1.8--3.7)      2.6 (1.7--4.2)      8.5    2.5 (1.7--4.0)      2.6 (1.7--4.2)      2.0
  Surgeon experience                                                     1.2                                            0.6
   Specialist\<20 years          701 (39.0%)         155 (39.5%)                141 (37.9%)         142 (38.2%)         
   Specialist≥20 years           1098 (61.0%)        237 (60.5%)                231 (62.1%)         230 (61.8%)         
  Thoracoscopic surgery          1199 (66.6%)        322 (82.1%)         36.1   292 (78.5%)         305 (82.0%)         8.8
  Anaesthesiologist experience                                           3.9                                            10.8
   Specialist\<15 years          810 (45.0%)         169 (43.1%)                183 (49.2%)         163 (43.8%)         
   Specialist≥15 years           989 (55.0%)         223 (56.9%)                189 (50.8%)         209 (56.2%)         
  Anaesthesia time (min)         315 (265--360)      300 (240--368)      8.4    300 (240--360)      300 (240--360)      1.4
  pRBC transfusion               203 (11.3%)         52 (13.3%)          6.0    51 (13.7%)          49 (13.2%)          1.6
  Year of procedure                                                      25.7                                           5.7
   2005--2009                    627 (34.9%)         69 (17.6%)                 74 (19.9%)          67 (18.0%)          
   2010--2012                    517 (28.7%)         157 (40.1%)                148 (39.8%)         145 (39.0%)         
   2013--2015                    655 (36.4%)         166 (42.3%)                150 (40.3%)         160 (43.0%)         
  Preoperative C/T±R/T           77 (4.3%)           21 (5.4%)           5.0    17 (4.6%)           20 (5.4%)           3.7
  Postoperative C/T              834 (46.4%)         163 (41.6%)         9.6    151 (40.6%)         158 (42.5%)         3.8
  Postoperative R/T              98 (5.4%)           22 (5.6%)           0.7    26 (7.0%)           21 (5.6%)           5.5
  Follow-up time, month          43.5 (25.3--72.4)   39.4 (21.9--59.9)   20.4   40.3 (24.4--62.2)   39.6 (21.9--59.8)   8.8

Values were mean ±SD, counts (%) or median (IQR). Continuous variables are analysed with Wilcoxon rank-sum tests; categorical variables are analysed with Pearson Χ^2^ tests. Standardised difference is the difference in mean, proportion or rank divided by the pooled SE, expressed as percentage; imbalance is defined as absolute value greater than 20 (small effect size).

ASA, American Society of Anesthesiologists; C/T, chemotherapy; CEA, carcinoembryonic antigen; COPD, chronic obstructive pulmonary disease; ECOG PS, Eastern Cooperative Oncology Group performance score; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; pRBC, packed red blood cell; R/T, radiotherapy.

###### 

Cancer stages and pathological features

                             Before matching   After matching                                      
  -------------------------- ----------------- ---------------- ------ ------------- ------------- -----
  **AJCC stage**                                                2.0                                1.8
  Stage I                    1316 (73.2%)      289 (73.7%)             271 (72.8%)   276 (74.2%)   
   IA                        546 (30.4%)       116 (29.6%)             114 (30.7%)   110 (29.6%)   
   IB                        770 (42.8%)       173 (44.1%)             157 (42.2%)   166 (44.6%)   
  Stage II                   205 (11.4%)       52 (13.3%)              55 (14.8%)    48 (12.9%)    
   IIA                       106 (5.9%)        26 (6.6%)               32 (8.6%)     24 (6.5%)     
   IIB                       99 (5.5%)         26 (6.6%)               23 (6.2%)     24 (6.5%)     
  Stage III                  278 (15.5%)       51 (13.0%)              46 (12.4%)    48 (12.9%)    
   IIIA                      253 (14.1%)       46 (11.7%)              42 (11.3%)    44 (11.8%)    
   IIIB                      25 (1.4%)         5 (1.3%)                4 (1.1%)      4 (1.1%)      
  **Pathologic features**                                                                          
  Subtype                                                       6.8                                5.1
   Adenocarcinoma            1511 (84.0%)      314 (80.1%)             292 (78.5%)   303 (81.5%)   
   SCC                       200 (11.1%)       54 (13.8%)              54 (14.5%)    46 (12.4%)    
   Other                     88 (4.9%)         24 (6.1%)               26 (7.0%)     23 (6.2%)     
  Tumour differentiation                                        5.3                                1.8
   Good                      181 (10.1%)       46 (11.7%)              39 (10.5%)    46 (12.4%)    
   Moderate                  1100 (61.2%)      215 (54.8%)             209 (56.2%)   201 (54.0%)   
   Poor                      516 (28.7%)       131 (33.4%)             124 (33.3%)   125 (33.6%)   
  Microscopic necrosis       388 (21.6%)       77 (19.6%)       4.8    77 (20.7%)    71 (19.1%)    4.0
  Lymphocytic infiltration   189 (10.5%)       27 (6.9%)        12.9   34 (9.1%)     27 (7.3%)     6.9
  Lymphovascular invasion    497 (27.6%)       127 (32.4%)      10.4   115 (30.9%)   118 (31.7%)   1.7
  Perineural infiltration    58 (3.2%)         12 (3.1%)        0.9    10 (2.7%)     11 (3.0%)     1.6

Values were counts (%). Categorical variables are analysed with Pearson Χ^2^ tests or Mann-Whitney U tests, as appropriate. Standardised difference is the difference in mean, proportion or rank divided by the pooled SE, expressed as percentage; imbalance is defined as absolute value greater than 20 (small effect size).

AJCC, American Joint Committee on Cancer; SCC, squamous cell carcinoma.

Association between thoracic epidural analgesia and recurrence-free survival {#s3a}
----------------------------------------------------------------------------

The 3-year and 5-year recurrence-free survival were 69.8% (95% CI 67.4% to 72.2%) and 64.4% (95% CI 61.9% to 66.9%) in the epidural group and 67.4% (95% CI 62.3% to 72.5%) and 62.8% (95% CI 57.1% to 68.5%) in the non-epidural group, respectively. No significant difference in the distribution of recurrence-free survival after lung cancer surgery was noted when comparing epidural with non-epidural group (p=0.54 by log rank test, [figure 2A](#F2){ref-type="fig"}). Moreover, epidural analgesia was not associated with better recurrence-free survival in patients stratified by cancer stages ([figure 2B](#F2){ref-type="fig"}).

![Unadjusted Kaplan-Meier curves for recurrence-free and overall survival of epidural and non-epidural groups. No significant difference in recurrence-free survival (A and B) or overall survival (C and D) after surgery for non-small-cell lung cancer was noted when comparing epidural with non-epidural group as a whole or stratified by cancer stage.](bmjopen-2018-027618f02){#F2}

The multivariable regression model indicated eight independent prognostic factors, including male (HR: 1.30), pretreatment CEA level (HR: 1.26, on base-10 logarithmic scale), cancer stage (II vs I, HR: 1.93; III vs I, HR: 2.85), tumour differentiation (moderate vs good, HR: 3.75; poor vs good, HR: 5.20), microscopic tumour necrosis (HR: 1.44), pathological lymphovascular invasion (HR: 2.05), and postoperative chemotherapy (HR: 1.46) and radiotherapy (HR: 1.44) ([table 3](#T3){ref-type="table"}). Adjusting for other covariates, the effect of epidurals on recurrence-free survival after lung cancer surgery was non-significant (HR: 0.93, 95% CI 0.76 to 1.14, p=0.47) in the multivariable analysis, similar to the results after propensity-score matching (HR: 0.97, 95% CI 0.71 to 1.3, p=0.82) and the quintile-stratified analysis (pooled HR: 0.94, 95% CI 0.76 to 1.15, p=0.53).

###### 

Multivariable analysis for cancer recurrence and all-cause mortality after model selection

                            Cancer recurrence                     All-cause mortality                                                      
  ------------------------- ------------------- ----------------- --------------------- ------------------------ ------- ----------------- ---------
  EA vs non-EA              0.927               0.755 to 1.139    0.473                 EA vs non-EA             0.811   0.582 to 1.129    0.214
  Sex (M vs F)              1.297               1.026 to 1.642    0.030                 Sex (M vs F)             1.969   1.344 to 2.882    0.001
  Pretreatment CEA\*        1.263               1.046 to 1.524    0.015                 ECOG PS≥1                1.494   1.105 to 2.019    0.009
  Postoperative C/T         1.456               1.187 to 1.786    \<0.001               Pretreatment CEA\*       1.672   1.221 to 2.290    0.001
  Postoperative R/T         1.443               1.126 to 1.849    0.004                 pRBC transfusion         1.402   1.008 to 1.948    0.045
  Stage                                                           \<0.001               Postoperative R/T        1.810   1.271 to 2.578    0.001
   II vs I                  1.927               1.521 to 2.440    \<0.001               Stage                                              \<0.001
   III vs I                 2.848               2.265 to 3.581    \<0.001                II vs I                 2.059   1.388 to 3.054    \<0.001
  Tumour differentiation                                          \<0.001                III vs I                2.964   2.032 to 4.323    \<0.001
   Moderate vs good         3.752               1.919 to 7.338    \<0.001               Tumour differentiation                             0.014
   Poor vs good             5.198               2.632 to 10.265   \<0.001                Moderate vs good        4.718   1.153 to 19.310   0.031
  Microscopic necrosis      1.444               1.203 to 1.733    \<0.001                Poor vs good            6.169   1.487 to 25.587   0.012
  Lymphovascular invasion   2.053               1.717 to 2.456    \<0.001               Microscopic necrosis     1.378   1.037 to 1.831    0.027

\*On base-10 logarithmic scale.

C/T, chemotherapy; CEA, carcinoembryonic antigen; EA, epidural analgesia; ECOG PS, Eastern Cooperative Oncology Group performance score; M, male; F, female; pRBC, packed red blood cell; R/T, radiotherapy.

Association between thoracic epidural analgesia and overall survival {#s3b}
--------------------------------------------------------------------

The 3-year and 5-year overall survival were 92.4% (95% CI 91% to 93.8%) and 85.8% (95% CI 83.8% to 87.8%) in the epidural group and 89.6% (95% CI 86.3% to 92.9%) and 84.3% (95% CI 80% to 88.6%) in the non-epidural group.

No significant difference in the distribution of long-term mortality after lung cancer surgery was found between the epidural and non-epidural groups ([figure 2C](#F2){ref-type="fig"}, p=0.13 by log rank test). In addition, no significant difference in overall survival was noted between the two groups in the subgroup analysis for distinct cancer stages ([figure 2D](#F2){ref-type="fig"}).

Nine independent prognostic factors were identified after the multivariable analysis ([table 3](#T3){ref-type="table"}), including male (HR: 1.97), ECOG performance score **≥**1 (HR: 1.49), pretreatment CEA level (HR: 1.67), cancer stage (II vs I HR: 2.06; III vs I, HR: 2.96), perioperative pRBC transfusion (HR: 1.40), tumour differentiation (moderate vs good, HR: 4.72; poor vs good, HR: 6.17), microscopic necrosis (HR: 1.38), pathological lymphovascular invasion (HR: 2.13) and postoperative radiotherapy (HR: 1.81). Multivariable analysis indicated no association between epidural analgesia and mortality in non-small-cell lung cancer after surgery (HR: 0.81, 95% CI 0.58 to 1.13, p=0.21). Propensity score matching generated similar results to the multivariable regression analysis (HR: 0.94, 95% CI 0.57 to 1.54, p=0.8) as well as the quintile-stratified (HR: 0.8, 95% CI 0.58 to 1.1, p=0.17) propensity score analyses.

Discussion {#s4}
==========

To our knowledge, this is the largest retrospective study applying propensity scoring methods to evaluate the impacts of epidural analgesia on oncological outcomes after lung cancer surgery. We found no evidence that epidural analgesia was associated with improved recurrence-free survival or overall survival in patients following surgical resection of non-small-cell lung cancer. Major clinicopathological prognostic factors were also taken into account in this study to estimate the adjusted effects of epidurals and avoid potential confounding effects from unbalanced distributions of important risk factors between the epidural group and its counterpart. From the perspective of methodology, we used propensity score matching to cancel out the potential imbalances in baseline characteristics and obtained similar results with those from traditional multivariable model. The combination of both analytical methods provided more persuasive proof than either of them did. Our study provided valuable information to reject the hypothesis of beneficial effect of epidurals on cancer recurrence or long-term survival after surgical resection of non-small-cell lung cancer with large sample size and considerable prognostic factors which were lacked in the previous survey.[@R16]

Perioperative immune function is an important determinant for metastases after cancer resection surgery. Anaesthetic management of cancer patients could impact long-term outcome, and potentially beneficial interventions include minimising the use of volatile anaesthetics and blood transfusion, administration of cyclooxygenase antagonists and statin, and hypothermia therapy.[@R27] However, whether regional analgesia reduces cancer recurrence after resection surgery remains inconclusive. The Cochrane review included four post-hoc analyses of previous controlled trials and indicated that current evidence for the benefit of regional anaesthesia on cancer outcome is inadequate due to limitations of study design and incomplete consideration of confounders.[@R28]

Although Cata and colleagues reported null results of epidural analgesia on recurrence-free and overall survival after lung cancer surgery,[@R16] they found an association between the intraoperative opioid consumption and recurrence-free survival or overall survival later only for stage I disease.[@R11] Our results did not support beneficial effects of epidural analgesia on oncological outcomes in patients stratified by cancer stages. This may be attributed to the difference in distributions of patient attributes or treatment modality. Maher and co-workers reported an association between increased opioid doses during initial 96 hours postoperative period and higher recurrence rate of non-small-cell lung cancer within 5 years.[@R12] However, they found no difference in intraoperative opioid administration among those with or without recurrence of lung cancer at the 5-year follow-up. The effects of regional block and opioid doses on long-term cancer outcomes in early-stage lung cancer await further investigation.

Our results showed perioperative blood transfusion is a risk factor for all-cause mortality, in line with previous literature.[@R19] In addition to mortality, allogenic blood transfusion may be associated with increased risk of cancer recurrence.[@R29] Transfused leucocytes can lead to immunomodulation, including changes in circulating lymphocytes, helper T-cell, suppressor T-cell ratios and B-cell function.[@R29] The meta-analysis by Churchhouse and colleagues examined the effect of blood transfusion on cancer recurrence and overall survival in patients undergoing surgical resection of lung cancer in 5378 patients. Though no definitive conclusions could be drawn, there appeared to be a relationship between transfusion and reduction of disease-free survival.[@R30] In our analysis, the association between blood transfusion and recurrence was non-significant after adjustment for covariates. This finding may imply that the potential impacts of other important confounders (eg, disease severity, presence of postoperative complications) may have a greater bearing on prognosis than the reception of blood itself.

As a sided observation, in the study period, the use of epidurals gradually decreased with concomitant increasing uses of thoracoscopic surgery. Thoracoscopic pulmonary resection for primary lung cancer has been demonstrated to achieve less postoperative pain, faster recovery, shorter hospitalisationand long-term survival comparable to that of open thoracotomy.[@R31] In our analysis, the distributions of thoracoscopic surgery and year of surgery between groups have been balanced after propensity score matching and are therefore unlikely to affect the results.

Several limitations are inherent in this retrospective observational study. First, patients were not randomised and clinical care was not standardised, so that potential selection bias and effects from unmeasured confounders cannot be excluded. Second, relatively small percentage (17.9%) of the patients was cared for without epidural analgesia. Third, the rate of epidural placement was lower in the latter years and this may result in longer follow-up period of epidural group. However, these imbalances have been cancelled out after propensity score matching. Fourth, it is difficult to determine the total narcotic consumptions for each patient due to the incompleteness of our electronic medical records.

In conclusion, our study rejected the association between epidural analgesia and cancer recurrence or long-term mortality in patients after surgery for stage I through III non-small-cell lung cancer. Prospective randomised trials are warranted to confirm or refute causal relationships between epidural analgesia and the long-term outcomes after lung cancer surgery.
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